The Computational Analysis of Novel Drug Opportunities (CANDO) platform is a computational approach to make drug discovery faster and less expensive while also being safe and effective. According to the University at Buffalo researchers who pioneered the platform, the impact on healthcare has been enormous. CANDO has also led to the creation of innovative biotech startups like AmritX, Meditati, and Mansarover Therapeutics, companies that are using the platform to develop treatments for non-small cell lung cancer, opioid use disorder, and aging, respectively.
CANDO is a project created by UB Clinical and Translational Science Institute (CTSI) Informatics Core Co-director Ram Samudrala, Ph.D., Professor and Chief, Division of Bioinformatics, Department of Biomedical Informatics, Jacobs School of Medicine and Biomedical Sciences, and is a featured application of the CTSI Informatics Core…
Read the full article here.
